How the Results of COMBI-AD and CheckMate-238 Will Impact Melanoma Care

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the results of the COMBI-AD study and the CheckMate-238 study will impact the care of patients with melanoma.

Related Videos